Maze Therapeutics (MAZE) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $110.00 | Sep 24, 2026 |
| Wedbush | Maintained | Outperform | $48.00 | Sep 23, 2026 |
| Citigroup | Initiated Coverage | Buy | $50.00 | Sep 23, 2026 |
| BTIG | Maintained | Buy | $46.00 | Sep 22, 2026 |
| BTIG | Maintained | Buy | $46.00 | Aug 12, 2026 |
| Truist Securities | Maintained | Buy | $64.00 from $68.00 | Apr 14, 2026 |
| JP Morgan | Maintained | Overweight | $58.00 from $52.00 | Mar 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $110.00 from $60.00 | Mar 25, 2026 |
| BTIG | Maintained | Buy | $46.00 | Mar 25, 2026 |
| Truist Securities | Initiated Coverage | Buy | $68.00 | Mar 18, 2026 |
| Wedbush | Maintained | Outperform | $58.00 from $43.00 | Mar 16, 2026 |
| Mizuho | Initiated Coverage | Outperform | $97.00 | Mar 10, 2026 |
| BTIG | Maintained | Buy | $46.00 | Mar 9, 2026 |
| Guggenheim | Maintained | Buy | $58.00 from $46.00 | Mar 4, 2026 |
| BTIG | Maintained | Buy | $46.00 from $37.00 | Jan 16, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $55.00 | Dec 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 from $50.00 | Dec 3, 2025 |
| Wedbush | Maintained | Outperform | $36.00 from $35.00 | Nov 7, 2025 |
| JP Morgan | Maintained | Overweight | $37.00 from $27.00 | Sep 29, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 | Sep 18, 2025 |
Frequently asked questions
What is the price target for MAZE stock?
The average 12-month analyst price target for Maze Therapeutics (MAZE) is $63.50, with a high estimate of $110.00 and a low of $46.00, across 4 analysts.
Is MAZE a buy, sell, or hold?
Analysts covering Maze Therapeutics currently average a Buy rating: 13 buy, 0 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for MAZE?
The average price target of $63.50 implies 142.09% upside from the last price of $26.23.
What is the latest analyst rating on MAZE?
On Sep 24, 2026, HC Wainwright & Co. maintained Maze Therapeutics at Buy with a price target of $110.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.